Research lead
Scientists at VIB, Belgium’s biotechnology institute, have identified a molecule that they say could form the basis for a new therapy for Alzheimer’s disease.
A hallmark of Alzheimer’s disease is the presence of amyloid plaques, which are abnormal accumulations of the β-amyloid protein between neurons. β-amyloid arises when the amyloid precursor protein is incorrectly cut by the γ-secretase enzyme complex. Although drugs acting on this target are in development they have run up against toxic side effects. The VIB researchers found that deactivating one variant, Aph1B γ-secretase, in Alzheimer mice reduces the formation of plaques, without causing harmful side effects.
γ-secretase is also involved in the onset of certain cancers, leading the researchers to suggest variants of γ-secretase could lead to new insights here as well.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
